Effectiveness of BNT162b2 mRNA vaccine third doses and previous infection in protecting against SARS-CoV-2 infections during the Delta and Omicron variant waves; the UK SIREN cohort study September 2021 to February 2022

Persistence of immune responses after heterologous and homologous third COVID-19 vaccine dose schedules in the UK: eight-month analyses of the COV-BOOST trial

(2023) Xinxue Liu et al.   JOURNAL OF INFECTION

Identifying and alleviating bias due to differential depletion of susceptible people in post-marketing evaluations of COVID-19 vaccines

(2022) Rebecca Kahn et al.   AMERICAN JOURNAL OF EPIDEMIOLOGY

SARS-CoV-2 breakthrough infections elicit potent, broad, and durable neutralizing antibody responses

(2022) Alexandra C. Walls et al.   CELL

mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant

(2022) Wilfredo F. Garcia-Beltran et al.   CELL

Association Between 3 Doses of mRNA COVID-19 Vaccine and Symptomatic Infection Caused by the SARS-CoV-2 Omicron and Delta Variants

(2022) Emma K. Accorsi et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization

(2022) Sandile Cele et al.   NATURE

Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies

(2022) Yunlong Cao et al.   NATURE

Neutralizing antibodies against the SARS-CoV-2 Delta and Omicron variants following heterologous CoronaVac plus BNT162b2 booster vaccination

(2022) Eddy Pérez-Then et al.   NATURE MEDICINE

Protection against SARS-CoV-2 after Covid-19 Vaccination and Previous Infection

(2022) Victoria Hall et al.   NEW ENGLAND JOURNAL OF MEDICINE

Duration of Protection against Mild and Severe Disease by Covid-19 Vaccines

(2022) Nick Andrews et al.   NEW ENGLAND JOURNAL OF MEDICINE

Protection against the Omicron Variant from Previous SARS-CoV-2 Infection

(2022) Heba N. Altarawneh et al.   NEW ENGLAND JOURNAL OF MEDICINE

SARS-CoV-2 Omicron variant: Antibody evasion and cryo-EM structure of spike protein–ACE2 complex

(2022) Dhiraj Mannar et al.   SCIENCE

Neutralizing antibody responses elicited by SARS-CoV-2 mRNA vaccination wane over time and are boosted by breakthrough infection

(2022) John P. Evans et al.   Science Translational Medicine

Vaccination before or after SARS-CoV-2 infection leads to robust humoral response and antibodies that effectively neutralize variants

(2022) Timothy A. Bates et al.   Science Immunology

Imprinted SARS-CoV-2-specific memory lymphocytes define hybrid immunity

(2022) Lauren B. Rodda et al.   CELL

Protection by vaccines and previous infection against the Omicron variant of SARS-CoV-2

(2022) Martin Šmíd et al.   JOURNAL OF INFECTIOUS DISEASES

Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant

(2022) Nick Andrews et al.   NEW ENGLAND JOURNAL OF MEDICINE

Immune Response 5–7 Months after Vaccination against SARS-CoV-2 in Elderly Nursing Home Residents in the Czech Republic: Comparison of Three Vaccines

(2022) Jan Martínek et al.   Viruses-Basel

Duration of mRNA vaccine protection against SARS-CoV-2 Omicron BA.1 and BA.2 subvariants in Qatar

(2022) Hiam Chemaitelly et al.   Nature Communications

Immune recall improves antibody durability and breadth to SARS-CoV-2 variants

(2022) Yuezhou Chen et al.   Science Immunology

Immunological memory to SARS‐CoV ‐2 infection and COVID ‐19 vaccines

(2022) Alessandro Sette et al.   IMMUNOLOGICAL REVIEWS

Neutralising antibody activity against SARS-CoV-2 VOCs B.1.617.2 and B.1.351 by BNT162b2 vaccination

(2021) Emma C Wall et al.   LANCET

Hybrid immunity

(2021) Shane Crotty   SCIENCE

Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial

(2021) Alasdair P S Munro et al.   LANCET

Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study

(2021) Noam Barda et al.   LANCET

Odds of Testing Positive for SARS-CoV-2 Following Receipt of 3 vs 2 Doses of the BNT162b2 mRNA Vaccine

(2021) Tal Patalon et al.   JAMA Internal Medicine

T-cell and antibody responses to first BNT162b2 vaccine dose in previously infected and SARS-CoV-2-naive UK health-care workers: a multicentre prospective cohort study

(2021) Adrienn Angyal et al.   Lancet Microbe

IgA dominates the early neutralizing antibody response to SARS-CoV-2

(2020) Delphine Sterlin et al.   Science Translational Medicine